IndraLab

Statements

Baricitinib inhibits ITCH. 1 / 1

| 1

reach

"At week 16, baricitinib 4-mg and 2-mg significantly reduced itch severity (Itch Numeric Rating Scale (NRS) (BREEZE-AD1: percent change from baseline -36.6% and -29.4% vs. placebo (-12.0%), p ≤.001 and p ≤.05; BREEZE-AD2: -47.2% and -46.9% vs. placebo (-16.6%), p ≤.001)."

33222559

INDRA sources:

Colored badges next to statement headings correspond to evidence counts from knowledge sources, as shown below. Badges to the left of the | separator correspond to curated knowledge base sources, and badges to the right of it correspond to machine reading systems.

IndraLab

Statements

Baricitinib inhibits ITCH. 1 / 1

INDRA sources:

Databases

Reading